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1. Introduction
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), 1, is a polychlorinat‐
ed pyridine cholesteryl carbonate, (Fig. 1) that is a derivative of 4-demethylpenclomedine (DM-
PEN, 2) [1-4]. The latter is a non-neurotoxic metabolite of penclomedine (PEN, 3, NSC 338720,
2-trichloromethyl-3,5-dichloro-4,6-dimethoxypyridine), that was identified during the NCI
sponsored Phase I clinical trials with 3 [4-8]. 3 was found to be active vs. advanced cancers but
possessed unacceptable neurotoxicity and discontinued from further study [5-10].
N
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Where –1. DM-CHOC-PEN: R=CO2-cholesteryl, 2. DM-PEN: R=H, 3. PEN: R=OCH3
Figure 1. Penclomedine (PEN) and Analogs
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1 was synthesized at DEKK-TEC as part of a series of polychlorinated pyridine carbonates and
carbamates that are lipophilic, non-neurotoxic alkylators of human xenograft brain and breast
tumors implanted intracranially (IC) in mice [1-3].
Anticancer activity for 1 has been well documented in vivo vs. IC implanted human xenograft
glioblastoma (U-251 and D-54) and breast cancer (MX-1) mouse models at doses lower or
equivalent to its LD10 [1-3]. Over 25 carbonate and carbamate analogs of 2 have been synthe‐
sized and evaluated in vivo and 1 was the most active of the analogs vs. the above IC implanted
human xenograft cancer models [1-3].
X-ray crystallography studies with 1 describe a perfectly linear configuration (Fig. 2) that
includes a neutral heterocyclic ring linked through a stable carbonate group to a lipophilic
cholesteryl moiety [2]. These basic characteristics plus the neutralizing effects (electrophilic)
of the polyhalogenated substitutions on the pyridine ring probably contribute to 1’s ability to
form micelle particles that penetrate the blood brain barrier, and accumulate in CNS tumor
tissues [1, 11].
Figure 2. Structural characteristics of 1
A mechanism of action has been proposed for 1 that involves cross-linking across the trichlor‐
omethyl group with tumor DNA in the major groove via N7-guanine cross linking in a G-X-C
sequence [1]. This mechanism of action would allow 1 to be administered in combination with
many of the clinically significant DNA major groove-alkylating drugs, that include methylat‐
ing agents [e.g. dacarbazine and temozolomide (TemodarR)] and chloroethylating agents [e.g.
bis(chloroethyl)-nitrosourea (BCNU) and clomesone] – all of which form carbonium ion-
mediated adducts via O6-guanine in contrast to binding with N7-guanine, as does 1 [12].
The pharmacokinetics, metabolic fate and toxicology of 1 in three animal species (mice, rats
and dogs) are reviewed here.
Cognitive/behavioral studies have been conducted in rats and dogs and are reviewed in depth.
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2. Materials and methods
2.1. Drug formulation and chemicals
1 and 2 were synthesized by DEKK-TEC, Inc., using GLP/GMP guidelines, as previously
described [1]. 1 is very stable in the solid state under ambient temperature and was adminis‐
tered in various vehicle media for the animal studies. For the rat studies, 1 was formulated as
a buffered emulsion of soybean oil (20%), egg yolk lecithin (10%), glycerin (3%), histidine
(3.1%) and water emulsion (containing 2-7 mg/mL of 1) [IND 86,876]. For the mouse and dog
IV studies, 1 was formulated as a 0.3% Klucel+0.3-3.3% Tween® 80, saline suspension and for
the oral mouse study an emulsion of 1 in a 8% Tween-80®/Neobee®-1053 (Squibb) solution was
used.
2.2. High pressure liquid chromatography (HPLC) analysis of 1 and a metabolite, 2
HPLC analysis was performed using an Agilent Technologies (New Castle, DE) 1200 model
HPLC fitted with a diode array UV detector set at a wavelength of 244 nm (λmax for 1). A
Rheodyne Model 7725 injection port (Cotati, CA, USA) with a 20µL sample loop was used to
inject the samples. Chromatograms were recorded with an Agilent Technologies integrator.
Samples were chromatographed using an Alltech 150 x 4.6 mµ column that contains Luna C8
(2) 100A packing (diameter of particles=5 mµ).
The mobile phase for 1 consisted of 80% THF: 20% water and for 2, was 45% THF: 47% water,
which was degassed, filtered through a 0.45 µm Rainin filter (Woburn, MA, USA) and
delivered at a flow rate of 1.0 mL/min.
Plasma and erythrocyte samples were stored at-74oC until analyzed. Standard solutions were
prepared by dissolving 6 mg of 1 or 2 in 20 mL THF. Internal standards were 20 mg of
cholesteryl benzoate (ChB, Sigma Aldrich Co) or phenol (P, Sigma Aldrich Co) each in 20 mL
THF. All solutions were stable for at least 2 months at 5o C. Standard assays for 1 and 2 consisted
of 0.25 mL of plasma, 25 µL of 1 or 2 and internal standard (ChB or P – 2 µL) and 2 mL
dichloromethane. The samples were vortexed for 10 min and frozen to separate the layers. The
bottom organic layer was removed with a 25 gauge needle and glass syringe, filtered through
a 0.45 mm Acrodisc syringe filter and evaporated to dryness under vacuum, reconstituted with
100 µL of THF and analyzed as below.
Control dog and rat whole blood and plasma samples were spiked with 1 in the concentration
range 5-1000 ng/mL, plus 20 µL of the above ChB. Similar controls were prepared for 2
(ng/mL) and its int. std. – P. Peak-area ratios of 1/ChB or (2/P) vs. the concentration of 1 or 2
(ng/mL) were subjected to linear regression analysis. Retention times for 1 and ChB were 6.41
and 4.63 min., respectively and for 2 and P were 6.6 and 18.5 min., respectively.
Verification of the HPLC assays included calibration curves derived from the assay of five (5)
erythrocyte and eleven (11) plasma standards in duplicate prepared each with 1 and 2 (0.5 ng/
mL-600 µg/mL). Plasma and erythrocyte samples were obtained from healthy rats and dogs
and spiked with 1 or 2 and their respective internal standards. Drug concentrations in all
Comparative Preclinical Pharmacology and Toxicology for…
http://dx.doi.org/10.5772/58353
241
samples were calculated using the results of linear regression analysis. Reproducibility was
higher than 85%. Limit of quantitation for 1 and 2 was 0.2 ng/mL.
2.3. P-glycoprotein (P-gp) transport studies
Cell lines-three (3) human cancer cell lines-A549: lung; MCF7: breast; and HeLa: ovarian were
obtained from ATCC, Manassas, MD, and maintained in culture in a temperature controlled
(36 oC), 5% carbon dioxide, and humidity controlled incubator system. All culture transfers
were in a laminar flow hood under sterile conditions. Tissue culture medium used was RPMI
1640 containing 10% FBS and penicillin/streptomycin/fungizone (1%) – all purchased from
InVitrogen.
Material preparation-Rho was prepared in distilled water as a stock solution (1 mg/mL), stored
frozen at-22o C. Rho (0.2µg/mL) was added to the culture medium in the presence or absence
of Vpml and/or 1. Vpml (2-23 µg/10 mL) was prepared in PBS solution and 1 (0.5-73 µg/10 mL)
in PBS+5% DMSO.
A typical assay-contained: 1-7.3 µg/mL, Vpml-2.5 µg/mL and Rho-0.2 µg/mL. Cells per test
system were 0.8-1.2 x 106/mL. Incubations occurred in the above incubator conditions for the
times and schedules discussed below. Experiments were conducted in triplicate and at times
as specified in the Results. Reaction incubations were 15-60 minutes in length as discussed in
the Results section.
Post incubation-After treatment, cells were rapidly trypsinized (~2 min), washed with cold
PBS and kept on ice until analyzed. Assay conducted with a Becton-Dickinson FACS-ARIA II
flow cytometer with CELLQUEST software. The Rho fluorescence was measured at laser
excitation 488 nm with emission at 530 nm and is expressed in arbitrary units compared to
control cells (untreated). Measurements were conducted on 10,000 cells per assay.
2.4. Animals
Adult Sprague-Dawley mice [Crl: CD1(ICR) BR] (males 20-25 g and female 18-25 g) and rats
[Crl: CD1(ICR) BR] (males 300-350 g and female 225-250 g) were obtained from Harlan
Industries (Indianapolis, IN), housed in groups of three-five per cage in light-controlled (12 h/
day) and temperature-controlled (24oC) animal isolators with filtered vents and exhausts. They
were fed a diet of Purina Laboratory Chow (Purina Feed) and received tap water ad libitum.
The rats were fasted and 3-4 mL of blood was drawn via the jugular vein. The order of bleeding
was alternated (one animal from each dose group, then repeating) to reduce handling and time
biases.
Adult male and female beagle dogs (6.5-7.5 mo. of age, 6.5-9.49 kg) were raised and maintained
at MPI Research (Mattawan, MI). They were fed a diet of Purina Dog Chow (Purina Feed),
received tap water ad libitum and exercised per IACUC protocol. Mouse, rat and dog were
euthanized with phenobarbital/ketamine anesthesia and/or carbon dioxide inhalation. The
chest cavities were exposed to insure death. Institutional animal care and use committees
(IACUC) reviewed and approved all the studies.
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All mice, rat and dog studies were conducted at MPI Research (Mattawan, MI) under GLP
regulations as described in the Guide for the Care and Use of Laboratory Animals, Office for
Laboratory Animal Welfare, NIH, Bethesda, MD.
For mouse toxicity studies, 1 was administered IV bolus via the tail vein or per oral gavage;
for the dog studies, 1 was administered as an IV bolus via the femoral vein and for rats,
administration was during a 3 h IV infusion via indwelling femoral vein catheters. The
observation period for all studies was 14-days – followed with euthanasia. For the rat and dog
studies, complete necropsies with complete blood pharmacokinetic parameters, hematology,
coagulation profiles, clinical chemistry and urine analyses were performed. For the mouse
studies physical/gross necropsy examinations were conducted.
For the acute behavioral studies, rats received drugs and controls to identify/verify gross
behavioral patterns employing a Morris modified water maze (4’ x 3’ x 1.5’) with a single layer
of white polyethylene peanuts that floated (in 6’’ of water) and covered a single mounting
stage [13, 14]. Adult female rats (Hsd:SD, 175-225 g.) were grouped 3-6 animals per drug arm.
The test agents were dissolved in or suspended in 5% aqueous TweenR 80-hydroxypropyl
cellulose in 5% saline and administered intraperitoneally (IP). Controls received the vehicle
only. Swimming trials began – 1, 2, 3 and 20 hours post-dosing. For each time period post-
dosing, the rats were challenged on six (6)-back-to-back swim trial events to find the platform.
The daily swimming times and ranges were compared to vehicle controls vs. chemotherapeu‐
tics alone in rats. The data (latency to find the platform) was analyzed by variance (ANOVA).
Body weights and water temperature-prior to each dosing and during each FOB assessment
were monitored.
2.5. Pharmacokinetic studies
Groups of rats (5/sex) were administered 100, 200, or 300 mg/kg of 1 as a 3 h timed infusion
and samples of blood collected (in EDTA tubes) at various time points IPEOI:-15,+10,+45 min,
1.5, 3, 6, 8, 12, 24 h and 14-days. Each animal possessed an indwelling femoral catheter for ease
of the study. The catheters were flushed after each blood draw. The plasma and erythrocytes
were separated and stored separately at -74oC until analyzed.
Adult beagle dogs (8 M) were administered 1 as a slow bolus injection once through a femoral
vein in doses of 10, 20, and 30 mg/kg. A 20-gauge venous catheter was inserted into a saphenous
vein for bleeding and samples were withdrawn at 0, 5, 15, and 30 min. and 1, 1.5, 2, 4, 8, 12 and
24 h into EDTA containing tubes. Plasma was separated and stored at-70o C until assayed.
Animals were anesthetized with ketamine.
2.6. Animal pharmacokinetic data analysis
Model parameters were estimated using Micropharm software and nonlinear least squares
regression was performed using Simplex and Gauss Newton algorithms []. An open two-
compartment model provided the best fit. Clearance, volume of distribution and half-lives
were derived from estimates of the model parameters.
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2.7. Data analysis
Data analysis was performed on all plasma and in vitro studies and analyzed via non-linear
regression using a non-weighed quasi-Newtonian/simplex fitting algorithm (Statistical
software available from Stat soft, Tulsa, OK).
3. Results
3.1. Stability studies
Bulk drug product, 1, as crystals, has been observed to remain stable for > four (4) years under
ambient conditions [1]. The final clinical product (2 mg/mL) was stored at refrigerator
temperatures (4-8o C) for 1.5 years without deterioration [15].
To further document product stability a 50:50 mixture of 1 (as the clinical product) with 10%
IntralipidR (Fresenius Pharmaceuticals) was infused at room temperature over 8 h into a sterile
container. Aliquots were withdrawn at 0, 0.5, 1, 2, 3, 4 h and analyzed by HPLC as described
above. Decomposition of 1 during an 8-hour infusion at room temperature was 6% (mean for
4-runs). The breakdown product, 2, could not be identified during this extended simulated
infusion study [11].
3.2. Toxicity
Acute oral and IV toxicity study results for 1 in mice, rats and dogs are presented in Table 1
which presents median lethal dose values observed. The oral study with mice failed to produce
toxicity at maximal administered doses of 0.8-2 g/kg. Volume restrictions prevented higher
escalations. The drug (oral) was not active in the xenograft models, thus additional oral
administration route studies were terminated. Two separate single IV mouse-dosing studies
calculated a LD10/50 of 136/385 mg/kg (for both sexes; with 95% confidence limits) – Table 1.
Specific lethal/sublethal values and details are discussed in Table 1.
Clinical signs generally reflecting the deteriorating state of both mice and rats post dosing were
observed in both sexes for 1 in a dose-dependent manner and included body surface staining,
decreased activity, lethargy, loss of appetite, decreased defecation, tremors, and/or whole-
body edema. The lethal experiences were sedation followed by respiratory arrest. No seizures
or loss of coordination was observed for the survivors.
3.3. Acute single dose intravenous studies in mice
Adult male and female mice, 10 animals per sex per dose level, were intravenously dosed with
50, 100, 200, 400 and 600 mg/kg. No animals died at 0 or 100 mg/kg, 1 animal died at both 50
and 200 mg/kg doses, 7 of 10 animals died at 400 mg/kg and 8 of 10 animals died at 600
mg/kg (Table 1). Various clinical signs reflecting treatment-related effects were noted in both
sexes, oftentimes in a generally dose-dependent manner. These clinical signs included
decreased activity, rapid/difficult/slow/shallow breathing, limbs splayed, tremors and skin
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cold to touch. No seizures or loss of coordination was noted. The deaths at 400 and 600 were
of a very immediate nature, occurring within minutes or less post-dose, with no clinical signs
exhibited prior to death. While transient incidences of rapid breathing were also noted in a
couple of control animals, a definitive relationship to the vehicle was unclear. No definitively
clear treatment-related body effects were noted in those mice surviving the 14-day observation
period when compared with controls. No macroscopic findings were noted in any animal at
necropsy.
Neither aplastic bone marrow nor splenic depletion of lymphocytes was noted.
Species No/ Sex Doses(mg/kg) Method LD10/50 (mg/kg) Time* (Days) Comments
Mice
36 M 50-600 IV 132/385 2-14 days Deaths were erratic
36 F Bolus (LD10/50)
Mice
30 M 800-2000 Oral – 0.8 – 2.0 g/d x 21 days
30 F Gavage 5d – no deaths No deaths
Rat
73 M IV 100 1-Rat died @ 100 mg/kg;
cholesterol – elevated, but
acceptable73 F 50-300 Infusion (LD10) 15 days
Dog
8 M IV
8 F 10-30 Bolus >30.0 10 days No deaths
Dog
4 M IV
4 F 10-30 Bolus >30.0 10 days No deaths
*The time of the last death.
Table 1. Medial dose summary for 1
Based on the conditions and findings of this study, the intravenous LD10 for 1 was calculated
to be 136 mg/kg (95% confidence limits could not be calculated) in mice (combined sexes),
while the intravenous LD50 was calculated to be 385 mg/kg (95% confidence limits).
3.4. Sub-chronic oral mouse toxicity (Table 1)
A study was conducted in groups of 10 male/10 female mice per dose. The study evaluated 1
administered daily for five days at doses of 0, 800, 1000, 1200, 1500 and 2000 mg/kg per gavage
to mice. Only one death occurred at 800 mg/kg on day 2 after dosing. All animals demonstrated
some degree of lethargy and unkempt appearance. Similar body appearances were noted with
the controls. No seizures were noted.
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3.5. Acute single dose intravenous studies in rats (Table 1)
A rat study was conducted with the objectives to evaluate and characterize acute toxicity,
maximum tolerated dose (MTD), and evaluate pharmacology (including pharmacokinetic
parameters) of 1 when intravenously (IV) administered over 3-hours, as an emulsion to rats.
The same formulation that is being administered to patients via IV infusion in clinical trials
was used for the rats (see Materials). A detailed clinical examination of each animal was
performed daily and included evaluations of the skin, fur, eyes, ears, nose, oral cavity, thorax,
abdomen, external genitalia, limbs and feet, respiratory and circulatory effects, autonomic
effects such as salivation, nervous system effects, including tremors, convulsions, reactivity to
handling, and psychological behavior.
Initially, a dose range finding (DRF) study was conducted that consisted of four (4) treatment
groups – each group included 3-M/3-F that were single dosed IV infusions and monitored –
no deaths were observed. The IV doses of 1 administered were – 50, 100, 150 and 200 mg/kg/
dose.
The main study phase consisted of a control group (10-M/10-F) that each received the vehicle
only and three groups (10-M/10-F) that each received a single IV infusion of 1 at dose levels of
100, 200 or 300 mg/kg. One male (1) rat in the 100 mg/kg group became moribund and was
euthanized. No animals died in the 200 or 300 mg/kg dosed groups. No external related body
effects were noted in the rats surviving the 14-day observation period. Both liver and spleens
were target organs noted to be enlarged and evaluated in detail as discussed below.
The rats were divided into 2-groups that were euthanized either on Day-2 or Day-15. Complete
macroscopic/microscopic examinations and complete clinical chemistry, hematology, coagu‐
lation studies and urinalysis were completed on all animals.
There were no meaningful hematological effects noted. On Day-2, erythrocytes, hemoglobin,
and hematocrit tended to be higher in the 300 mg/kg/dosed group. These changes were most
likely a result of fluid imbalances relative to reduced water intake. Monocytes were increased
in both sexes at 200 and 300 mg/kg/dose and lymphocytes were decreased in males at 300 mg/
kg/dose. Neutrophils were elevated in all groups on Days-2 and 15 and were attributed to
stress and/or route of administration. All other changes were resolved by Day-15 and all values
returned to normal pre-drug limits.
There were no test article-related effects on coagulation parameters or on urine analysis values.
The most significant findings were 1’s related effects on the clinical chemistry analytes in the
lipid profile studies (Table 2). Both alterations in the cholesterol and triglyceride profiles were
significantly affected post dosing with 1. Cholesterol and 2 are formed following the metabo‐
lism of 1 by the liver and/or peripherally (Scheme 1). The total cholesterol levels significantly
increased in all groups vs. the control vehicle group. Increased levels of LDL-cholesterol were
the pre-dominant variant observed on Day-2. However, by Day-15 the total cholesterol levels
had returned to within normal limits and the total cholesterol was predominantly accounted
for as a HDL-variant.
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Parameter Day Vehicle 100 mg/kg 200 mg/kg 300 mg/kg
(mg/dL) (M/F) (M/F) (M/F) (M/F)
Cholesterol 2 50/ 49.4 106.4a /77.8 206.4b/157.4 b 188b/165.6 b
(Total) 15 36.8/63.6 45.5/63.6 49.6a/48.8 51.8 a/61.4
HDL-variant 2 27.4/34.4 33.6/36.8 25.2/30.8 25.6/28.8
15 26.6/51.8 32.3/51.2 35.6 a /40 37.8 b/49.6
LDL-variant 2 134/5.4 66.0/31.3 210.2/142.6 183.6/156
15 6.6/4.4 7.5/5.6 7.2/4.4 6.8/4.4
Triglycerides 2 38.8/29 54.8/40 109.8 a/45.8 81/110.6
15 36.6/43.8 37.3/34.4 33.8/28.4 46.2/30.8
No of animals in each group – 5; aSignificantly different from control (p<0.05); bSignificantly different from control
(p<0.01).
Table 2. Summary of lipid profiles in rats dosed with 1 as an IV infusion (Day 1)
The triglycerides also increased in the 200 and 300 mg/kg groups on Day-2 post-dosing, which
resolved by Day 15. The females demonstrated the most significant elevations in both trigly‐
cerides and LDL-cholesterol. On Day 15 the profiles for both total cholesterol and triglycerides
had returned to WNL. Table 2 reviews cholesterol and triglyceride trends.
Alanine aminotransferase (ALT) in males, and γ-glutamyl transferase (GGT), and alkaline
phosphatase in females were minimally to mildly elevated at the 300 mg/kg/dose on Day 2.
All of the findings noted on Day-2 had resolved by Day-15.
Various clinical signs reflecting treatment-related effects were noted, mostly lethargy that
cleared. No behavioral alterations were noted.
Macroscopic/microscopic examinations revealed increased sizes of the livers and spleens. On
Day-2, the 200 and 300 mg/kg groups possessed vacuolated macrophages in the liver (Kupffer
cells) and spleen. By Day-15 the macrophages contained smaller oil aggregates and clusters
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Scheme 1. Metabolism of 1
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within hepatic sinusoids. The findings in both the spleen and the liver showed trends toward
resolution by Day-15 with both biliary hyperplasia in the liver and splenic focal necrosis
resolving; vacuoles were smaller and cell cytoplasm had a more eosinophilic tint seen in both
livers and spleens, albeit the vacuoles still expanded the cytoplasm of the cells. The latter
changes are artifacts resulting from the extraction of drug/lipids/cholesterol from hepatic/
splenic macrophages during fixation/preparation of tissues for microscopic examination. The
changes seen on Day-2 in the spleens and the livers trended towards resolution by Day-15.
Controls (vehicle alone) did not demonstrate the above changes.
Transitory changes in the hepatic profile are considered 2o to stasis of 1 in hepatic sinusoids
with biliary congestion that results in cysts and shunting of blood to the spleen resulting in
splenic cysts and fatty deposits.
Although the above findings resolved by Day-15, they must be considered adverse – based on
the degree of elevation in triglycerides (3-fold) and LDL-cholesterol (30-fold in females) seen
in some groups. The control group received the vehicle alone – soybean oil and egg yolk lecithin
– both rich in triglycerides and did not demonstrate abnormal lipid profiles or the liver/spleen
changes.
Based on the conditions and findings of this study, the intravenous LD10 of 1 in rats was
calculated to be 100 mg/kg (95% confidence limits could not be calculated) – Table 1.
3.6. Acute dog IV toxicity (Tables 1, 3)
A single IV dose study was performed in adult Beagle dogs, which consisted of 1 administered
once as an IV bolus. Sixteen (16) adult beagle dogs (8 male and 8 female) divided into three
groups received a single intravenous injection of 1. The experimental design and results are
presented in Table 3.
No treatment related effects on survival, hematology, urinalysis, or macroscopic and micro‐
scopic evaluations were noted during the study. Numerous clinical signs reflecting treatment-
related effects were noted in both sexes of all groups, including the control group, and
exhibited no dose-dependent pattern, clearly suggesting that the effects were attributable to
the 0.3% Klucel+1.92% Tween 80 vehicle rather than 1. Pertinent clinical signs noted included
decreased activity, emesis, impaired righting reflex, limb function impaired, breathing slow/
shallow, red skin discoloration (entire body, ears, or face), swelling (face and/or nose/muzzle),
skin cold to touch, eyes swollen, slow gum capillary refill time, feces-mucoid/soft/discolored/
watery, lacrimation, salivation, sclera injected, vocalization, tremors, and urination decreased.
The effects were of immediate onset (within one hour post dose), with most of the signs clearing
by Day 2 of the study. However, decreased activity persisted for Days 2, 3, or 4 in some of the
animals and through the remainder of the study. No clear treatment-related body weight
effects were noted during the study when comparing treated groups vs. controls. Slight body
weight losses were noted in some animals which were non-dose related. The latter observa‐
tions were in all probability attributable to the vehicle.
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Route/Schedule Dose (mg/kg) Number and Sex Observations
IV once
0 2M 2 F No deaths
10 2 M 2 F No deaths
20 2 M 2 F No deaths
30 2 M 2 F No deaths
Table 3. Acute IV toxicity in the dog
There were marked elevations of alanine aminotransferase (ALT), and sorbitol dehydrogenase
(SDH) in males in both controls and all treated animals on Day 2. Increased aspartate amino‐
transferase (AST) was observed in one (1) male with remarkably increased values for AST,
ALT and SDH. The other male in this group exhibited only mildly increased values on Day 2
for these parameters. Similar trends were noted in females. ALT and SDH were highest on
Day 2 for all dose levels, including controls. This acute and transient effect on liver enzymes
exhibited no dose-dependent pattern and attributable to the vehicle. The latter finding was not
observed to this extent in the rat study which used a different vehicle. The above was verified
in a second group of 4M/4F.
The dog hematological studies confirmed that the 10-30 mg/kg doses do not produce myelo‐
suppression, thrombocytopenia or anemia.
Treatment-related neurotoxicity was not observed following the single IV bolus administra‐
tion of 1 to dogs. A second opinion review was obtained (RT), who conducted silver stains and
confirmed MPI’s observation that there were no microscopic pathological CNS changes
present in the brains of dogs treated with 1 (FDA IND – 68,876) [14].
3.7. Summary Median Lethal Dose (Single Dose)
Table 1 summarizes the toxic effects of single IV dose administrations of 1 in mice, rats and
dogs. Three intravenous studies were conducted under FDA GLP guidelines. The summary
of the median lethal single dose (LD50) values were calculated by combining the data from the
acute single dose studies according to species and are available only for mice and dogs.
3.8. Acute rat behavioral studies
Rats in groups (5-females) received 1, 2, or 3 in a dose range finding (DRF) screen to identify
and verify gross behavioral patterns (Table 4). Documentation of drug cognitive/learning
abilities were conducted in a Morris modified water maze with adult female rats (Hsd:SD,
175-225 g.) which were grouped 3-6 animals per drug arm (Table 5).
Impaired learning behavior has not been observed for 1 or 2 in contrast to observed data for 3
during the first 1-3 h and at 20 h periods post-dosing (Table 5). A vehicle and a 5-FU control
were included for comparison. The observations noted for 3 and 5-FU support the literature
reports that both drugs impair memory in patients receiving the drug [16-18]. The described
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assay is a simple, reproducible quantitative assessment of impaired visuospatial cerebellar-
learning/memory and performance functions via swimming and navigating a water maze. The
treated and control rats were timed to navigate to find a hidden platform – Figures 3 and 4.
Figure 3. A rat on the water maze platform.
A control memory impairment agent, MK-801, is included to demonstrate complete impale‐
ment. In contrast, 1 and 2 had little or no influence on learning/memory, while 3 produced
long lasting impairment.
Drug Dose (mg/kg) IP 1 - 4 Hours 5th Hour 7th Hour
Vehicle (Controls) 0.5 mL Alert; normal behavior Alert; normal behavior Alert; normalbehavior
Mk-801 (control) 0.05 once Lethargic Lethargic Lethargic
5-FU (Chemo Control) 78 Lethargy, eyes closed More alert Normal behavior
3 400-800 once Eyes closed; spastic;lethargy Less lethargy; spastic Normal behavior
2 350-600 once No acute toxicity; nospasms Normal behavior Normal behavior
1 100 & 300 once No acute toxicity; nospasms Normal behavior Normal behavior
Table 4. Rats - gross behavior patterns (5 female rats per group, 160-168 g)
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3.9. Brain/tumor penetration
Adult male mice (athymic NCr-nu/nu – NCI-Frederick Production Area, NCI) were sedated
and intracerebrally (IC) implanted with U251 glioma cells (106) from tissue culture. The mice
were divided into 5-control and 5-treated with 1. The latter group was administered 1 (135 mg/
kg/day) IP daily for two consecutive days (q1d x 2) beginning 4-days post inoculation of cells.
Four hours after the second treatment the animals were sacrificed and the brains removed
intact (cerebellum included), flash frozen in liquid nitrogen and stored at -77 oC until assayed.
The intact frozen brains (~1.3 g) were coronal sliced into three sections in a mouse brain blocker
(Kopf). The encapsulated gliomas were easily identified and separated readily from normal
brain tissue with a scalpel and using microscopic ‘touch finger printing’ – separation verified.
The tumor tissues were weighed, pooled and homogenized in 10 mL saline at 5OC. This process
was repeated for the normal brain tissue. The cold homogenates were separately extracted
with 10 mL dichloromethane, the organic layer separated and evaporated to dryness.
The residues were dissolved in dichloromethane and underwent preparative TLC on silica gel
plates (Sigma-Aldrich, Milwaukee, WI) with a mobile phase – hexane/dichloromethane:10/30.
The respective spots for 1 and 2 were extracted with dichloromethane, concentrated and
analyzed by HPLC (for procedure, see-Methods). 1 and 2 were present in the gliomas extracts
-62 and 11 ng/g, resp. (avg.) were present in the gliomas, but none in the normal brain tissue.
Figure 4. A rat swimming through the peanuts.
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Five (5) control mice bearing IC implanted U251 cells (non-treated) were used as the dissection
and extraction controls. No chemicals were identified in the above extraction assays or in the
brains from the control tumor/normal mice.
3.10. Normal brain penetration
Adult male rats [Crl: CD1(ICR) BR] (325-350 g wt) in groups of 5 animals were dosed intra‐
peritoneally with 50 mg/kg of DM-CHOC-PEN in 0.3% Klucel/Tween80/saline daily x 2 days.
On the 3nd day the rats were sacrificed and the intact brains removed (~1.9 g) and each
homogenized in 10 mL saline at 5OC. To the cold homogenates, 20 mL dichloromethane was
added and shaken for 30 minutes. The organic layer was removed and evaporated to dryness
under vacuum at room temperature. The residues were dissolved in 1 mL of tetrahydrofuran
TREATMENTS
LEARNING - IMPROVEMENT
(MEAN) *[ DIFFERENCE
BETWEEN 1st AND 6th TEST –
SAME TIME PERIOD]
MEMORY – IMPROVEMENT/IMPAIRMENT
[Differences Between 1 – 20 hrs]
Agent
Dose
(mg/kg/
dose
#Rats Schedule
1 Hr 2 Hr 3 Hr 20 Hr
1Hr→ 2Hr→ 3Hr→
1 Hr →2 Hr 3 Hr 20 Hr
Fold↑ Fold↑ Fold↑ Fold↑ Fold↑ Fold↑ Fold↑ 20 Hr
(Overall)
Fold ↑ Time
(sec)
Control Saline 24 _ 3.2 1.3 2.1 2.0 3.0 0.7 1.6 3.5 35.1
MK-801 0.05 3 QD X 1 0** 0** 0** 0** 0 0 0 0 0
5-FU 78 6 QD X 1 1.7 1.3 1.7 8.2 1.0 0.6 1.3 0.7 -13.5
3 400 6 QD X 1 0.8 1.3 0.6 1.2 1.4 1.7 0.6 1.0 -1.2
2 135 6 QD X 1 6.7 1.5 1.7 2.4 4.0 1.0 1.0 3.5 42.1
1 100 6 QD X 1 3.2 1.3 1.8 3.8 3.2 0.6 1.5 2.4 23.6
*Rats were tested – six (6) separate trials – 1, 2, 3 and 20 hrs post dosing. The rats are timed to swim to the stage. The
fold improvements are recorded in the table. For hours 1, 2, 3, and 20 post dosing, two values are given for each drug.
The first number (X) for each hour is the difference (in seconds) between the initial and final attempts (first – sixth run).
A negative number indicates complete lack of learning throughout six runs – taking a longer amount of time on the sixth
try than the first. The next value (indicated with *) is X fold performance improvement. This is calculated by initial/ final
time. <1 indicates complete lack of improvement (taking longer on the last try than the first). Doses used were the
therapeutic values as determined from the tumor models.
**MK-801-is a NMDA (N-methyl-D-aspartate) inhibitor that produced a solemn effect that prevented the rats from
swimming and learning. After 3-days the rats were equivalent vs. control. 5-FU has been associated with memory loss in
patients treated with chemotherapy (17).
Table 5. Evaluation of the behavioral activity of penclomedine analogs in female rats
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and 100 µL chromatographed on silica gel plates with hexane:dichloromethane (1:1) as solvent.
DM-CHOC-PEN was identified at Rf 0.74 with an additional spot – Rf 0.51. All spots were cut
out, extracted with THF and analyzed by HPLC. DM-CHOC-PEN and a polar metabolite were
identified by HPLC (see below).
DM-CHOC-PEN was calculated to be present-100 ng/g (avg.) of whole brain. The more polar
peak (Rf 0.51) was not DM-PEN and present at 20 ng/g of whole brain. 1H-NMR of the latter
fraction identified a pair of peaks at δ 5.68 & δ 5.75-consistent with loss of a methylene chlorine
and binding to an NH-group, possible adduct. The material possessed a cholesteryl carbonate
moiety. Normal brain tissue was used as a control.
3.11. Pharmacokinetic studies in rats and dogs (Table 5)
Plasma concentration-time profiles for 1 in adult rats post a 3-hour single dose IV infusion of
100, 200 and 300 mg/kg are presented in Fig. 5. Mean pharmacokinetic parameters for rats
summarized in Table 6, Figs. 5 and 6 were – T1/2α 15+/-7 h, T1/2β 19.1+/-1.3 h and CL 22.2+/-6.5
L/h for 1, which could be detected 24 h post infusion. As mentioned previously and outlined
in Scheme 1, 1 is metabolized to 2 and cholesterol, which are compared in Fig. 6 for the 100
mg/kg dose. The levels of 2 and cholesterol paralleled each other, as expected.
Figure 5. Mean plasma levels for 1 IPEOI – 4-rats per group.
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Figure 6. Mean plasma and rbc levels for 1, 2 and cholesterol, IPEOI for 1 after IV infusion (200 mg/kg) – 4-rats per
group.
The shifts noted in the bioavailability for 1 vs. 2 are suggestive of an enzyme overload – a
Michaelis Menten effect (Fig. 6). For rats, the AUC and Cmax values vs. doses of 1 administered
were linear – Figs. 7 & 8. Dog pharmacokinetics for 1 are compared to the rat values in Table.
For dogs, plasma clearance was constant between 10 and 30 mg/kg. The plasma clearance is
328.8 L/h vs. 346.8 L/h; demonstrating the PK linearity of 1. Differences seen between rats and
dogs are due to the fact that rats received 1 during a 3-hr IV infusion and dogs via an IV bolus
injection – thus not comparable.
Dose Specie (N) T1/2 α (h) T1/2β (h) AUC (mg*h/L) Cl (L/h)
10 mg/kg Dog (4) 1.23 (Mean) 21.6 (Mean) 0.42 (Mean) 328.8 (Mean)0.53 (SD) 16.00 (SD) 0.17 (SD) 221.2 (SD)
30 mg/kg Dog (4) 0.63 (Mean) 18.7 (Mean) 1.12 (Mean) 346,8 (Mean)0.09 (SD) 10.7 (SD) 0.09 (SD) 54.5 (SD)
100 mg/kg Rat (5) 0.51 (Mean) 2.48 (Mean) 1.05 (Mean) 30.4 (Mean9.990.05 (SD) 0.8 (SD) 0.53 (SD) (SD)
200 mg/kg Rat (5) 0.25 (Mean) 6.94 (Mean) 3.46 (Mean) 16.9 (Mean)0.1 (SD) 2.1 (SD) 0.46 (SD) 4.04 (SD)
300 mg/kg Rat (5) 0.12 (Mean) 4.0 (Mean) 5.17 (Mean) 19.40 (Mean)0.06 (SD) 1.2 (SD) 1.74 (SD) 9.13 (SD)
(Males & females combined)
Table 6. Comparative PK parameters of 1 in rats and dogs
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Figure 7. AUC vs. dose for 1
Mean  rat [C] max  vs dose
0 100 200 300 400
0.0
0.5
1.0
1.5
DM-CHOC-PEN (mg/kg)
[C
] m
ax
 
(m
g/
L)
Figure 8. [C]maxvs. dose for 1
3.12. P-glycoprotein (P-gp) transport (Table 6)
The results of incubating Rho in the presence or absence of Vpml and/or 1 are summarized in
Table 7.
Six reaction conditions (1-6) are reviewed, where:
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1 – is the result from incubating cell lines with Rho for 15 minutes.
2 – is the result from incubating cell lines with Vpml for 1 hour and then adding Rho during
the last 15 minutes of incubation.
3 – is the result from incubating the cell lines with Vpml for 15 minutes, adding 1 after an
incubation time of 30 minutes and then adding Rho during the last 15 minutes – total incubation
time, 60 minutes.
4 – is the result from treating the cell lines simultaneously with Vpml and 1 for 45 minutes and
then adding Rho and continuing the incubations for an additional 15 minutes – total incubation
time – 60 minutes.
5 – is the result from incubating the cell lines with 1 for 15 minutes and then adding Vpml for
additional 45 minute incubation. Rho is added during the last 15 minutes of the incubation.
Finally, 6 is the result of incubating each of the cell lines for 1 hour with 1 alone and then adding
Rho during the last 15 minutes of incubation.
The results summarized in Table 7 for the 3 sensitive cell lines are coherent: The rate of
incorporation of Rho is lower when cells are treated by the mixture of Vpml and DM-CHOC-
PEN or Vpml alone but not when the cells are treated with DM-CHOC-PEN alone (mean
fluorescence intensity of 6 roughly the same for control cells). This is interpreted as meaning
that DM-CHOC-PEN has no effect on the function of P-gp transport.
Cell Line
Mean Fluorescence Intensity for Total Cells (Mean) (x 103)*
Rho Vpml + Rho Vpml → DM + Rho Vpml + DM +Rho DM + Vpml + Rho DM + Rho
1 2 3 4 5 6
HeLa 19.3** 15.0 15.6 18.2 16.0 17.6
A549 23.2 20.8 16.4 13.2 17.9 21.8
MCF-7 10.5 6.5 5.9 6.2 7.4 8.9
*Cell concentration per each assay. Average of triplicate assays.
Table 7. P-glycoprotein transport of 1
4. Discussion
The rationale for the pre-clinical development of 1, a polychlorinated pyridine cholesteryl
carbonate, was based on observed antitumor activity vs.  IC implanted human xenografts
growing in mice, in comparison with standard therapy [1,2]. 1 was synthesized during an
attempt to design and develop polychlorinated pyridine carbonates that could penetrate
the  BBB,  with  cytotoxic  activity  vs.  intracranially  growing  brain  tumors  and  without
neurotoxicity [1,2].
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We report here the results of acute toxicity and pharmacology studies with single intravenous
injections of 1 in groups of rodents and dogs. The end-point of all the studies was to identify
drug toxicity and an acceptable starting dose for a Phase I clinical trial in humans with
advanced cancer.
The IV LD10 single-dose value for mice (sexes combined) was calculated as 139 mg/m2. The
mouse study generally displayed a typical dose-response effect (with the exception of one
death at 50 mg/kg), with 1 being slightly more toxic in males than in females at the two highest
doses.
A sub-chronic oral mouse toxicity study was conducted at MPI Research, Mattawan, MI, under
GLP conditions in male/female mice. The study evaluated 1 in an emulsion administered per
oral gavage daily for five days at doses of 0, 800, 1000, 1200, 1500 and 2000 mg/kg per gavage
to mice. Only one death occurred at 800 mg/kg on day 2 after dosing. All animals demonstrated
some degree of lethargy and unkempt appearance, but no seizures. Similar body appearances
were noted with the controls.
Adult rats were treated once with single IV infusions of 1 in doses of 50, 100, 150, 200, and 300
mg/kg. One (1) death occurred at the 100 mg/mL dose level. No deaths occurred in the treated
vehicle group. There were no meaningful effects on hematology parameters. On Day-2
erythrocytes, hemoglobin, and hematocrit tended to be higher at the 300 mg/kg/dose. These
changes were most likely a result of fluid imbalance. Monocytes were increased in both sexes
at 200 and 300 mg/kg/dose and lymphocytes were slightly decreased in males at 300 mg/kg/
dose level. Neutrophils were elevated relative to expected ranges in all groups on Days-2 and
15 and were attributed to stress and/or route of administration. All other changes were
resolved by Day 15 and all values returned to normal pre-drug limits. There were no test article-
related effects on either coagulation or on urinalysis parameters.
The most significant abnormal findings were the statistically increased plasma values for
cholesterol and triglycerides in the 200 and 300 mg/kg treated groups. LDL-cholesterol was
significantly elevated in females – increased from 5.4 to 142 and 156 mg/dL for the 200 and 300
mg/kg groups, resp. This elevation is significant and considered a SLT (CTEP.v4). The
triglycerides were increased by 4-fold in the 300 mg/kg group females, however, they return
to normal values by Day-15. Hepatic and splenic deposits of fats were also noted on gross and
microscopic examinations which cleared by Day-15.
Cholesterol is released during metabolism of 1 (Table 2 & Scheme 1). The early formation of
LDL-cholesterol is not a surprise since the formation of the LDL-variant is the initial natural
method to ‘initially encase cholesterol molecules’. The cholesterol is cleared through the liver
as the HDL-variant. Triglycerides were elevated secondary to increased cholesterol and the
lipid character of the emulsion vehicle, which also rapidly reversed [3].
Although the above cholesterol and triglyceride findings resolved by Day-15, they must be
considered adverse – triglycerides (3-fold) and LDL-cholesterol (30-fold in females). The
control group received the vehicle alone – soybean oil and egg yolk lecithin – both rich in
triglycerides and did not demonstrate abnormal lipid profiles.
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Alanine aminotransferase (ALT) in males, and γ-glutamyl transferase (GGT), and alkaline
phosphatase in females were minimally to mildly elevated in the 300 mg/kg group on Day-2.
All of these findings on Day-2 resolved by Day-15. Transient elevations in transaminases were
considered to be 2o to hepatic clearance of the drug. Neither gross nor microscopic evidence
of toxicity (other than hepatic cysts) was noted at autopsies, including CNS. Table 7 compares
calculated starting therapeutic doses for humans [19].
A single IV dose administration study was performed in adult beagle dogs employing single
doses (10 – 30 mg/kg) of 1. No treatment related fatalities occurred. Numerous clinical signs
reflecting treatment-related effects were noted in both sexes of all groups. Pertinent clinical
signs noted included decreased activity, autonomic hyperactivity – vomiting, decreased
urination, salivation, and lacrimation. The effects were of immediate onset (within one hour
post dose), with most of the signs clearing by Day-2 of the study. However, decreased activity
persisted for Days 2, 3, and 4 in some of the animals and through the remainder of the study.
Slight body weight losses noted in some animals were not dose-dependent and it could have
been attributable to the clinical signs (and associated stress) caused by the vehicle. There were
marked elevations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
sorbitol dehydrogenase (SDH) noted in controls and all treated groups and apparently
attributable to the vehicle – a Klugel/Tween mixture that will not be used in the clinical studies.
All liver functions reversed by Day-15. This acute and transient effect on liver enzymes
exhibited no dose-dependent pattern and was also apparently attributable to the vehicle. The
latter finding was not observed in the rat study.
No hematological deficiencies were noted in any group. Drug-related neurotoxicity was not
observed. This was confirmed by second opinion (RT), who conducted silver stains and
confirmed MPI’s observation that there were no microscopic pathological CNS changes
present in the brains of dogs treated with 1 [19].
Based on the conditions and findings of this study, a single bolus intravenous injection of 1 to
groups of beagle dogs at dose levels of 10, 20 and 30 mg/kg produced no effects that were
directly related to the test article; instead they were probably attributable to the 0.3% Klucel
+1.92% Tween® 80 vehicle used.
Pharmacokinetic studies were conducted in two species – rats and dogs. Parameters were
obtained from Gauss Newton algorithm modeling [3]. The values are compared in Table 6. No
statistical differences between male and female rats were noticed. The differences in half life
can be explained in reference to administration routes – dog-IV bolus vs. rat – IV infusion over
3 hrs. Similarly, the clearance is higher in the bolus studies as expected with a surge of drug
being filtered.
In the learning/cognitive screening study, rats treated with 3 took a longer period of time to
find the pedestal vs. 1, 2 and the controls. Despite normal gross appearance of the rats after 7
hr (Table 4), the 3 treated animals demonstrated impaired learning (Table 5). There were no
signs of learning impairment noted in the rats treated with 1 or 2, as was seen for 3. 2 is a
polychlorinated 4-hydroxypyridine (Fig. 1) and exists as a zwitterion that is too polar to cross
the BBB. This behavior has been observed for other 4-hydroxypyridines [20]. The water
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swimming maze assesses impaired visual spatial processing, as well as memory. The obser‐
vations for 5-FU (drug control) confirmed literature reports of learning/memory impairment
post dosing in humans [16].
The drug penetrated human glioblastoma tumor tissue growing IC in mice, with none
detectable in the normal tissue. This only reinforced our interest in using the drug to treat
patients with cancers involving the CNS.
1 does not have effects on the P-gp transport system. In the current study, Rho was selected
as an indicator of 1’s interaction/inhibition with the P-gp protein transport system in three (3)
human cancer cell lines-A549: lung; MCF7: breast; and HeLa: ovarian. Verapamil (Vpml) is a
known inhibitor of the P-gp pathway and was included as a positive control, providing
additional support that 1 is not a substrate for the P-gp transmitter system and not rejected via
the high energy ATP-binding cassette (ABC) transport systems [11].
Both 1 and 2 bind to erythrocytes and could penetrate the blood brain barrier (BBB) and IC
growing cancers attached to rbcs via breaks in the BBB (penetration routes of metastatic
cancers) or sites of neo-angiogenic networks. However, as previously published, 2 alone is not
active vs. IC implanted human breast and glioma tumors implanted in a mouse model; the
presence of 2 in the IC implanted tumors (see Results-Brain/tumor penetration) must be due to
IC steroid esterase hydrolysis of 1 [21].
Thus, preclinical studies, conducted under GLP guidelines are presented as support for 1 to
enter Phase I clinical trials as treatment for advanced cancer with CNS involvement. Table 8
reviews calculated starting doses and data satisfied the FDA’s requirements for an IND (IND
68,876), which has completed a Phase I clinical trial – DTI-021 [19]. The phase I clinical trial is
nearing completion with acceptable toxicities and responses noted in patients with advanced
cancer involving the CNS system [15].
Drug Species Acute IV LD10 Comparable Human IV Dosage*
DM-CHOC-PEN Mouse 136 mg/kg/d 39 mg/m2/d (10% of LD10)
DM-CHOC-PEN Rat 100 mg/kg/d 60 mg/m2 (10% of LD10)
DM-CHOC-PEN Dog >30 mg/kg/d >100 mg/m
2/d**
(1/6th HNSTD)
* Standard conversion **Based on the highest dose – 30 mg/kg used in the dog studies
The initial level of dosing in the Phase I clinical trial has been established as 39 mg/m2 (IND 86,876) (19).
Table 8. Estimated comparable human intravenous dosages
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